O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+2.19%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.03B
AUM Growth
+$5.03B
(-7.7%)
Cap. Flow
-$321M
Cap. Flow
% of AUM
-6.38%
Top 10 Holdings %
Top 10 Hldgs %
44.26%
Holding
122
New
8
Increased
22
Reduced
23
Closed
12
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$60.8M |
| 2 |
Integer Holdings
ITGR
|
$40.4M |
| 3 |
argenx
ARGX
|
$24.7M |
| 4 |
Exact Sciences
EXAS
|
$22.5M |
| 5 |
Amgen
AMGN
|
$22.3M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$106M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$103M |
| 3 |
Janux Therapeutics
JANX
|
$54.3M |
| 4 |
Esperion Therapeutics
ESPR
|
$36.7M |
| 5 |
Praxis Precision Medicines
PRAX
|
$28.1M |
Sector Composition
| 1 | Healthcare | 99.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Scholar Rock
SRRK
$3.3B
| $8.95M | 0.18% |
1,074,382
-2,500,250
| -70% | -$20.8M |
|
|
TSBX
77
DELISTED
Turnstone Biologics
TSBX
| $8.12M | 0.16% |
3,099,265
| – | – |
|
78
Passage Bio
PASG
$22.7M
| $8.04M | 0.16% |
10,124,576
| – | – |
|
79
Progyny
PGNY
$2.02B
| $7.44M | 0.15% |
259,900
+146,600
| +129% | +$4.19M |
|
80
C4 Therapeutics
CCCC
$182M
| $6.99M | 0.14% |
+1,513,058
| New | +$6.99M |
|
|
IMA
81
ImageneBio, Inc. Common Stock
IMA
$153M
| $5.84M | 0.12% |
3,539,358
| – | – |
|
82
Amicus Therapeutics
FOLD
$2.42B
| $5.66M | 0.11% |
570,300
| – | – |
|
83
Krystal Biotech
KRYS
$4.35B
| $5.5M | 0.11% |
29,966
-7,200
| -19% | -$1.32M |
|
84
InspireMD
NSPR
$101M
| $5.32M | 0.11% |
2,133,405
| – | – |
|
85
Perspective Therapeutics
CATX
$251M
| $4.91M | 0.1% |
492,670
-6,013,130
| -92% | -$1.57M |
|
86
Structure Therapeutics
GPCR
$1.14B
| $4.91M | 0.1% |
+125,000
| New | +$4.91M |
|
87
Nkarta
NKTX
$149M
| $4.73M | 0.09% |
800,000
| – | – |
|
88
BiomX
PHGE
$14.1M
| $4.63M | 0.09% |
13,773,653
+9,256,064
| +205% | +$3.11M |
|
89
Verastem
VSTM
$585M
| $4.56M | 0.09% |
1,529,115
| – | – |
|
90
Fate Therapeutics
FATE
$115M
| $4.45M | 0.09% |
1,355,352
| – | – |
|
91
X4 Pharmaceuticals
XFOR
$70M
| $4.14M | 0.08% |
7,133,515
| – | – |
|
92
Invivyd
IVVD
$218M
| $2.67M | 0.05% |
2,425,800
-264,500
| -10% | -$291K |
|
93
Milestone Pharmaceuticals
MIST
$151M
| $2.64M | 0.05% |
2,000,000
| – | – |
|
|
ELEV
94
DELISTED
Elevation Oncology
ELEV
| $2.54M | 0.05% |
941,275
| – | – |
|
95
TG Therapeutics
TGTX
$5.03B
| $2.37M | 0.05% |
+133,200
| New | +$2.37M |
|
|
96
BioMarin Pharmaceuticals
BMRN
$11.3B
| $2.15M | 0.04% |
26,100
-1,252,400
| -98% | -$103M |
|
|
CMMB
97
Chemomab Therapeutics
CMMB
$15.7M
| $2.05M | 0.04% |
2,241,273
-1
| -0% | -$4 |
|
98
Oric Pharmaceuticals
ORIC
$1.03B
| $2.03M | 0.04% |
287,100
| – | – |
|
99
NextCure
NXTC
$13.3M
| $1.81M | 0.04% |
1,141,200
| – | – |
|
100
Apollomics
APLM
$4.62M
| $1.81M | 0.04% |
8,565,456
| – | – |
|